Original Report

Impact of a telehealth intervention on quality of life and symptom distress in patients with head and neck cancer


 

Background Patients undergoing treatment for head and neck cancer commonly experience significant changes in quality of life (QoL) and levels of symptom distress. It is not known if a telehealth intervention would mitigate these changes.
Objective To evaluate the impact of a telehealth intervention on QoL and symptom burden in patients undergoing initial treatment for head and neck cancers.
Methods A randomized clinical trial comparing the impact on QoL and symptom distress of telehealth intervention and standard care was conducted with 80 patients (45 treatment, 35 control) who had been diagnosed with head or neck cancer and were receiving 1 or more treatment modalities. Treatment group participants responded daily to symptom management algorithms using a simple telehealth messaging device. QoL was evaluated by the Functional Assessment of Cancer Therapy-Head&Neck Scale (FACT-HN) and symptom burden by the Memorial Symptom Assessment Scale (MSAS). Control group participants completed assessments while they received routine care.
Results In the posttreatment phase, the telehealth participants had significantly better scores than the controls for physical well-being (20.6 vs 17.0, P = .02) and trial outcome index (59.9 vs. 50.2, P = .04) on the FACT-HN, and total scores on the MSAS (0.9 vs. 1.2, P = .04).
Limitations The moderate sample size of 80 patients limits the power to measure more subtle impacts of the intervention.
Conclusions Using telehealth to provide support to patients with head and neck cancer during the acute phase of treatment improved some aspects of posttreatment QoL and symptom burden.
Funding Supported in part by NIH R21CA115345 from the National Cancer Institute.

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

A wonderful life
MDedge Hematology and Oncology
Impact of aprepitant on emesis control, dose intensity, and recurrence-free survival in a population-based cohort of head and neck cancer patients receiving high-dose cisplatin chemotherapy
MDedge Hematology and Oncology
Total thyroidectomy more likely with younger thyroid cancer patients
MDedge Hematology and Oncology
High failure rate seen with limited parathyroidectomy in patients with MEN-1
MDedge Hematology and Oncology
AHRQ releases update on radiotherapy for head and neck cancer
MDedge Hematology and Oncology
HIM Study: Prevalent HVP-16 infections tend to persist
MDedge Hematology and Oncology
Postdiagnosis imaging increasing for patients with all stages of thyroid cancer
MDedge Hematology and Oncology
Sunitinib elicits “exceptional” response in refractory thymic carcinoma
MDedge Hematology and Oncology
Study aims to determine prognostic factors for subset of thyroid cancer patients
MDedge Hematology and Oncology
Beneficial effects of animal-assisted visits on quality of life during multimodal radiation-chemotherapy regimens
MDedge Hematology and Oncology